Molecular insights into mammalian end-binding protein heterodimerization by de Groot, C O et al.
University of Zurich
Zurich Open Repository and Archive
Winterthurerstr. 190
CH-8057 Zurich
http://www.zora.uzh.ch
Year: 2010
Molecular insights into mammalian end-binding protein
heterodimerization
de Groot, C O; Jelesarov, I; Damberger, F F; Bjelić, S; Schärer, M A; Bhavesh, N S;
Grigoriev, I; Buey, R M; Wüthrich, K; Capitani , G; Akhmanova, A; Steinmetz, M O
de Groot, C O; Jelesarov, I; Damberger, F F; Bjelić, S; Schärer, M A; Bhavesh, N S; Grigoriev, I; Buey, R M;
Wüthrich, K; Capitani , G; Akhmanova, A; Steinmetz, M O (2010). Molecular insights into mammalian
end-binding protein heterodimerization. Journal of Biological Chemistry, 285(8):5802-5814.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
Journal of Biological Chemistry 2010, 285(8):5802-5814.
de Groot, C O; Jelesarov, I; Damberger, F F; Bjelić, S; Schärer, M A; Bhavesh, N S; Grigoriev, I; Buey, R M;
Wüthrich, K; Capitani , G; Akhmanova, A; Steinmetz, M O (2010). Molecular insights into mammalian
end-binding protein heterodimerization. Journal of Biological Chemistry, 285(8):5802-5814.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
Journal of Biological Chemistry 2010, 285(8):5802-5814.
 1
MOLECULAR INSIGHTS INTO MAMMALIAN END BINDING PROTEIN 
HETERODIMERIZATION 
Christian O. De Groot1,6, Ilian Jelesarov2, Fred F. Damberger3, Saša Bjelić1, Martin A. Schärer1, 
Neel S. Bhavesh3,7, Ilia Grigoriev4, Ruben M. Buey1, Kurt Wüthrich3,5, Guido Capitani1,  
Anna Akhmanova4, and Michel O. Steinmetz1* 
1Biomolecular Research, Structural Biology, Paul Scherrer Institut, CH-5232 Villigen PSI, Switzerland, 
2Biochemisches Institut der Universität Zürich, Winterthurerstrasse 190, CH-8057 Zürich, Switzerland, 
3Institute of Molecular Biology and Biophysics, ETH Zurich, CH-8093 Zurich, Switzerland, 4Department 
of Cell Biology, Erasmus Medical Center, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands, 
5Department of Molecular Biology and Skaggs Institute for Chemical Biology, The Scripps Research 
Institute, La Jolla, CA 92037, USA. 6Present address: Ludwig Institute for Cancer Research, Department 
of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, CA 92093, USA. 
7Present address: Structural and Computational Biology Group, International Centre for Genetic 
Engineering and Biotechnology (ICGEB), New Delhi 110067, India 
Running head: Dimerization properties of EB proteins 
Address correspondence to: Michel O. Steinmetz, Biomolecular Research, Structural Biology, Paul 
Scherrer Institut, CH-5232 Villigen PSI, Switzerland.  
Phone:+41-56-310-4754. Fax: +41-56-310-5288. E-mail: michel.steinmetz@psi.ch 
 
Microtubule plus-end tracking proteins 
(+TIPs) are involved in many microtubule-
based processes. End binding (EB) proteins 
constitute a highly conserved family of 
+TIPs. They play a pivotal role in regulating 
microtubule dynamics and in the 
recruitment of diverse +TIPs to growing 
microtubule plus ends. Here we used a 
combination of methods to investigate the 
dimerization properties of the three human 
EB proteins EB1, EB2 and EB3. Based on 
Förster resonance energy transfer we 
demonstrate that the C-terminal 
dimerization domains of EBs (EBc) can 
readily exchange their chains in solution. We 
further document that EB1c and EB3c 
preferentially form heterodimers, whereas 
EB2c does not participate significantly in the 
formation of heterotypic complexes. 
Measurements of the reaction 
thermodynamics and kinetics, homology 
modelling and mutagenesis provide details 
of the molecular determinants of homo- 
versus heterodimer formation of EBc 
domains. Fluorescence spectroscopy and 
nuclear magnetic resonance studies in the 
presence of the CAP-Gly domains of either 
CLIP-170 or p150glued, or of a fragment 
derived from APC show that chain exchange 
of EBc domains can be controlled by binding 
partners. Extension of these studies of the 
EBc domains to full-length EBs demonstrate 
that heterodimer formation between EB1 
and EB3, but not between EB2 and the other 
two EBs, occurs both in vitro and in cells as 
revealed by live cell imaging. Together, our 
data provide molecular insights for 
rationalizing the dominant negative control 
by C-terminal EB domains, and form a basis 
for understanding the functional role of 
heterotypic chain exchange by EBs in cells.  
 
INTRODUCTION 
 
Microtubules are filamentous structures 
involved in many vital cellular activities. They 
contain two structurally and functionally 
distinct ends, slow-growing minus ends and 
fast-growing plus ends, and are thus 
intrinsically polar (reviewed in (1,2)). In cells, 
the microtubule minus ends are often anchored 
to the microtubule organizing center and are 
thus stable, whereas microtubule plus ends are 
highly dynamic and stochastically switch 
between phases of growing and shortening. The 
intrinsic dynamic nature of microtubules is 
central to microtubule function and is tightly 
regulated both spatially and temporally by so-
called microtubule associated proteins (MAPs). 
Microtubule plus-end tracking proteins (+TIPs) 
are a functionally and structurally diverse set of 
MAPs that specifically accumulate to and track 
growing microtubule plus ends. They play 
important roles in controlling microtubule 
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dynamics and in conferring recognition of 
microtubule ends in all eukaryotes (reviewed 
by (3,4)).  
 Prominent representatives of +TIPs are 
end binding proteins (EB). EBs constitute a 
highly conserved and ubiquitously expressed 
family of proteins that recently emerged as core 
components of dynamic +TIP interaction 
networks at growing microtubule plus ends (4). 
Besides regulating microtubule plus end 
dynamics, they are implicated in several vital 
microtubule-based processes, including 
maintenance of cell polarity, regulation of 
chromosome segregation, positioning of the 
mitotic spindle, and anchoring of microtubules 
to their nucleation sites (4,5). EBs 
autonomously track microtubule tips 
independent of additional factors, most likely 
by recognizing a structural feature of the 
growing microtubule plus end (6-10). 
Moreover, EBs play an essential role in 
targeting a diverse range of +TIP binding 
partners to microtubule ends (4).  
 EBs comprise about 300 residues and 
contain highly conserved N- and C-terminal 
domains that are separated by a more variable 
linker sequence (4). The globular N-terminal 
moiety shows the characteristic features of 
calponin homology (CH) domains and is 
necessary and sufficient for microtubule 
binding (11). The C-terminal domain (EBc) 
contains an α-helical parallel coiled-coil, which 
mediates the dimerization of EB polypeptide 
chains (12). It partially overlaps with the 
unique EB homology (EBH) domain which 
contains a four-helix bundle and a disordered 
C-terminal tail (12,13). The EBH domain 
specifically recognizes SxIP motifs embedded 
within basic and serine-rich sequence regions 
(14). The phosphorylation-controlled EBH-
SxIP interaction is necessary and sufficient for 
targeting numerous structurally and 
functionally unrelated +TIPs to microtubule 
plus ends, including the adenomatous polyposis 
coli (APC) tumor suppressor protein, the 
microtubule-actin crosslinking factor (MACF), 
cytoplasmic linker protein (CLIP-170)-
associated proteins (CLASPs), the 
transmembrane protein stromal interaction 
molecule-1 (STIM1), and the mitotic 
centromere-associated kinesin (MCAK). The 
SxIP motif thus acts as a widespread 
‘Microtubule tip Localization Signal’, MtLS 
(14). The C-terminal 20- to 30-residue tails of 
EBs share a highly conserved C-terminal 
tripeptide, denoted the EEY/F motif. The 
EEY/F motif with the carboxylate group of the 
terminal aromatic residue is specifically 
recognized by the highly conserved GKNDG 
motif of cytoskeleton-associated protein-
glycine-rich (CAP-Gly) domains present in, for 
example, CLIP-170 and the large dynactin 
subunit p150glued (15,16).  
 In mammals, the EBs are represented 
by three proteins, EB1, EB2 (RP1) and EB3 
(EBF3), which are encoded by separate genes 
(17). So far, functional studies have been 
primarily focused on EB1, but it is becoming 
increasingly clear that in spite of their high 
sequence conservation, the individual EBs 
exhibit different regulatory and functional 
properties. For example, EB2 displays lower 
affinity than EB1 and EB3 for several well-
characterized binding partners, such as APC 
and MCAK, and is thus less likely to be 
involved in their targeting to microtubule plus 
ends (18,19). EB3 was also found to bind to the 
F-actin-binding protein drebrin (20) and the E3 
ubiquitin ligase SIAH-1 (21), whereas no such 
interactions were observed for the other EBs. 
These observations support the view that the 
individual mammalian EBs can differentially 
bind to partners. The EBs also exhibit different 
spatial and temporal expression patterns. In 
contrast to EB1 and EB2, EB3 is upregulated in 
neurons and muscle cells (22-24) and plays an 
important role in myotube differentiation (23) 
and neuronal development (20,22). 
Furthermore, a phosphorylation controlled 
interaction between EB3 and SIAH-1 regulates 
EB3 degradation and hence expression levels 
during the cell cycle, whereas no such 
regulation was observed for EB1 and EB2 (21).  
 We have recently documented that 
mammalian EBs differentially affect 
microtubule dynamics (9). EB1 and EB3 
promote persistent microtubule growth by 
suppressing catastrophes (a switch from the 
growing to the shrinkage phase of a 
microtubule). By comparison, EB2 is much less 
potent; this functional difference is partially 
due to amino acid substitutions in the CH 
domain of EB2. Although both in vivo and in 
vitro studies revealed that CH domains are 
sufficient for tracking growing microtubule 
plus ends, dimerization was shown to be 
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necessary for the anti-catastrophe activity of 
EB proteins (9). In this context, we reported 
that the EBs can also form heterodimers 
through their C-terminal domains (9). 
Differences or changes in the dimerization 
properties of the three EBs may therefore 
contribute to the differences in the anti-
catastrophe activity. Interestingly, C-terminal 
EB dimerization domains act as dominant 
negative mutants and have been used in an 
array of cellular studies as tools to interfere 
with the activity of endogenous EB proteins 
(9,20,25-32). They were found to affect all EB 
species by removing them from microtubule 
plus ends, which results in an increase in the 
catastrophe frequency (9).  
 The molecular basis of EB dimerization 
and the mechanism underlying the dominant 
negative effect of EBc domains is poorly 
understood. Acquiring knowledge of these 
properties is, however, important to understand 
the different functions of mammalian EB 
proteins and to interpret data obtained in the 
presence of transiently overexpressed EBc 
domains in cells. Moreover the dimerization 
properties of EB proteins are likely to play a 
role in regulatory mechanisms used by EBs to 
control microtubule dynamics. Using a 
combination of biochemical, biophysical, 
structural, and cell biological methods together 
with computational modelling, this paper 
provides molecular insight into the mechanism 
of EB dimerization and its regulation by +TIPs 
binding partners.  
 
EXPERIMENTAL PROCEDURES 
 
Cloning and mutagenesis 
For all EB constructs, DNA was PCR-
amplified from human EB1, EB2, and EB3 
full-length cDNA clones kindly provided by 
W. Bu and L. Su (18). The insertion of EB1c 
(Asp191–Tyr268) into the bacterial expression 
vector pET15b (Invitrogen) has been described 
(33). To create a tag-less version of EB1c, a 
PCR-amplified EB1c fragment was ligated 
between the NcoI and BamHI sites of pET15b 
(Invitrogen). Gateway cloning (Invitrogen) of 
EB3c (Ala200-Tyr281) into a pDEST17 vector 
has been previously described (9). 
 N-terminal fluorescent protein-tagged 
EB1c, EB2c (Thr242-Tyr327) and EB3c 
constructs were generated as follows. First, 
monomeric variants of enhanced cyan 
fluorescence protein (mECFP) and enhanced 
yellow fluorescence protein (mEYFP) were 
generated using pECFP-C1 and pEYFP-C1 
vectors (Clontech) as DNA templates. Next, 
PCR products of mECFP and mEYFP were 
inserted by a PCR-splicing method (34) into 
pET15b between the regions encoding for the 
hexahistidine tag and the thrombin cleavage 
site. The thrombin cleavage site and the BamHI 
site were part of the 11-amino acid linker 
SGLVPRGSSDP introduced between the 
fluorescent proteins and EBc domains. The 
antisense primer used in this step also 
introduced two stop codons followed by an 
EcoRI restriction site. Finally, PCR-amplified 
EBc domains were ligated between the BamHI 
and EcoRI sites.  
 For bacterial expression of full-length 
EB1 and EB3, PCR-amplified DNA was 
ligated into the pET28a vector (Invitrogen) 
between the NcoI and BamHI sites, where the 
intrinsic BamHI site in EB2 was silently 
mutated. These plasmids were used to generate 
C-terminal fluorescent-protein-tagged EB full-
length constructs. PCR amplified fluorescent 
protein DNA fragments were derived from 
pmECFP, pmEYFP, pmEGFP-N1 and 
pmCherry-N1 (Clontech) and ligated between 
the BamHI and XhoI sites to provide all 
constructs with a C-terminal hexahistidine tag. 
The insertion of p150CG (Met18-Ser111 of 
human p150glued) and the construction of the 
p150CG[A49M] mutant in pET15b has been 
described in (33). The Gateway cloning of 
ClipCG2 (Arg210-Gly282 of human CLIP170) 
is reported in (15). All mutagenesis was carried 
out using the PCR-based QuikChange site-
directed mutagenesis protocol from Stratagene. 
 
Protein and peptide preparations 
The E. coli strain BL21(DE3) (Stratagene) was 
used for all protein expressions. Bacteria were 
grown to an OD600 of 0.8 in LB medium at 
37°C containing the appropriate antibiotic. 
Cultures were induced by addition of IPTG to a 
final concentration of 0.5 mM and protein 
expression was performed at 22°C for 16 h. For 
the preparation of uniformly 15N-labeled EB1c, 
cells were grown in a minimal medium as 
previously described (35).  
 Hexa-histidine-tagged fusion proteins 
were purified by immobilized metal-affinity 
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chromatography on HisTrap Ni2+-Sepharose 
chelating columns (GE Healthcare) at 4°C 
according to the manufacturer's instructions. In 
order to remove the His-tag the recombinant 
proteins were dialyzed against thrombin 
cleavage buffer (20 mM Tris-HCl, pH 7.4, 
supplemented with 150 mM NaCl, and 2.5 mM 
CaCl2) and proteolytic cleavage was carried out 
for 16 h at 4°C using human thrombin (Sigma) 
at a concentration of 3 U per milligram of 
recombinant protein. The processed proteins 
were reapplied to immobilized metal-affinity 
chromatography to separate digested proteins 
from the hexahistidine tag and from uncleaved 
protein.  
 Uniformly 15N-labeled EB1c 
containing no affinity tag were purified by ion 
exchange chromatography using a self-packed 
ResourceQTM FastFlow 10/5 column (GE 
Healthcare) equilibrated in binding buffer (20 
mM Bis-Tris, pH 6.0, supplemented with 5 mM 
NaCl, and 2 mM DTT) at 4 °C. After sample 
loading, the column was washed with 20 
column volumes of binding buffer. Bound 
proteins were eluted by applying a linear 
gradient of NaCl (0-0.5 M) in the same buffer. 
All processed protein samples were gel-filtered 
on a SEC HiLoadTM Superdex 200 16/60 
column (GE Healthcare) equilibrated in PBS, 
pH 7.5, supplemented with 2 mM DTT, and 1 
mM EDTA.  
 The N-acetylated and C-amidated 
APCp1 (Val2781-Lys2819 of human APC) 
peptide was assembled on an automated 
continuous-flow synthesizer employing 
standard methods. 
 The homogeneity of the proteins and 
peptides was confirmed by either 15% SDS-
PAGE (proteins) or HPLC followed by mass 
spectral analysis (APCp1). The concentrations 
of protein and peptide solutions were 
determined by tyrosine and tryptophan 
absorbance at 280 nm.  
 
Fluorescence assay 
Förster resonance energy transfer (FRET) 
measurements at 37°C were carried out in PBS, 
pH 7.5, supplemented with 2 mM DTT and 1 
mM EDTA. 50 µl protein solutions were 
analyzed in 384-well plates (black flat-bottom; 
Greiner No. 781900) covered with optical clear 
adhesive seal (ABsolute QPCR Seal (AB-
1170), Thermo scientific) in a TECAN Saphir 
II plate reader. A minimal excitation/emission 
bandwidth of 5 nm was used. The gain and the 
Z-position were set manually to 85 and 10’000 
µm, respectively. Emission spectra were 
recorded between 450 and 650 nm and 
excitation was performed at 434 nm. For 
kinetic measurements, FRET fluorescence was 
recorded at 527 nm. 10 readings per time point 
with an integration time of 40 µs were 
collected. For data analysis, three kinetic traces 
or spectra were averaged. Kinetic half-lives 
were calculated by single-exponential fitting 
using MATLAB version 7.8 (The MathWorks, 
Inc.). Standard deviations from the average 
values were < 5 %.  
 
Static light scattering (SLS) 
SLS experiments were performed on a 
miniDawn TriStar system equipped with an 
Optilab rEX refractometer (Wyatt Technology 
Corp) coupled to a Superdex 200 10/30 
(Amersham Biosciences) size-exclusion 
chromatograpgy (SEC) column run on an 
Agilent 1100 HPLC. 100 µl of 20 μM protein 
solutions were injected at a constant flow rate 
of 0.5 ml/min onto the column equilibrated in 
PBS supplemented with 2 mM DTT and 1 mM 
EDTA. The molecular masses of the eluted 
proteins were determined with the Wyatt Astra 
version 5.3.1.5 software package (Wyatt 
Technology Corp.).  
 
Circular dichroism (CD) spectroscopy 
CD experiments with EBc domains were 
performed on a J-715 instrument (Jasco Ltd., 
Japan) equipped with a computer-controlled 
water bath, using cylindrical jacketed cuvettes 
of 1 mm optical path length. Thermal melting 
curves were recorded with 50 µM protein in 
PBS, pH 7.5, supplemented with 2 mM DTT 
and 1 mM EDTA, by continuous heating at 1 
deg min−1. Data points (ellipticity at 222 nm) 
were collected every 10 seconds. Reversibility 
was determined from the recovery of the mean 
residue ellipticity (MRE222) after cooling, and 
was always found to be better than 95%. 
Thermal melting curves were analyzed 
according to a two-state model as described in 
(36). For measurements of urea melting curves, 
40 μM of protein was incubated overnight at 
the corresponding urea concentrations. The 
signal was averaged for 3 minutes after thermal 
equilibration. Urea-induced equilibrium 
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unfolding experiments were analyzed by non-
linear least-squares regression according to 
well-established procedures (37).  
 
Stopped-flow kinetics 
Kinetic experiments with EBc domains were 
performed with the π*-180 instrument (Applied 
Photophysics). The dead time was 1-2 ms and 
the optical path length was 10 mm. Refolding 
was initiated by mixing one volume of buffered 
protein solution (PBS, pH 7.5, supplemented 
with 2 mM DTT and 1 mM EDTA) containing 
8-9 M urea with 10 or 25 volumes of buffer, or 
with buffer containing various concentrations 
of the denaturant. Unfolding rates were 
measured by 1:10 dilution of the protein into 
solutions containing final urea concentrations 
higher than the mid-point of equilibrium urea 
unfolding. The detection wavelength was 225 
nm and the slits were set to 4 mm. 10-15 
mixing experiments were averaged for each 
kinetic trace. Unfolding traces were modeled 
with a single-exponential function to extract the 
rate constants for unfolding (ku) using the 
software provided by the manufacturer. The 
rate constants for refolding (kf) in urea were 
calculated as described previously (36). Linear 
extrapolation to 0 M denaturant of the 
corresponding limbs in plots of ln kf,u versus 
[urea] yielded the kinetic constants in the 
absence of urea (38).  
 
Structural modeling 
All dimeric forms of human EBc domains 
(EB2c-EB2c, EB3c-EB3c, EB1c-EB2c, EB1c-
EB3c, EB2c-EB3c) were modeled based on the 
X-ray structure of human EB1c-EB1c at 1.54 Å 
resolution (PDB code 1WU9). The EB1c 
homodimer structure was used as a dimeric 
template in Modeller 9v6 (39), allowing for 
simultaneous energy minimization of both 
chains in the homo- or heterodimers. A 
multiple-sequence alignment of human, murine 
and rat EB1c, EB2c and EB3c was used as the 
basis for the modeling process. The homo- or 
heterodimeric models thus obtained were 
geometry-regularized with PHENIX 1.4 (40). 
Fig. 3, B to E, was prepared using PyMOL 
(41).  
 
Nuclear magnetic resonance (NMR) 
The previously obtained NMR assignments for 
the 1H and 15N backbone resonances of EB1c in 
the free form and in complex with APCp1 at 
45°C in 10 mM potassium phosphate buffer at 
pH 6.5 (14) were used as a starting point to 
obtain assignments at 37°C in 10 mM 
potassium phosphate buffer at pH 6.5 
containing 150 mM NaCl (“NMR buffer”). A 
series of [15N,1H]-HSQC spectra obtained at 45, 
42.5, 40, and 37°C was used to transfer the 
assignments from 45°C to 37°C. Amide proton 
exchange experiments were initiated by 
dissolving the lyophilized protein in 2H2O and 
measuring a series of [15N,1H]-HSQC spectra at 
various time intervals. The first experiment was 
measured approximately 10 minutes after 
dissolution in 2H2O. Residues with 
exchangeable amide signals, which were 
present in the spectrum obtained in 1H2O but 
absent in the first spectrum obtained in 2H2O 
are identified as “undergoing fast exchange”. A 
lower limit on the exchange rate of these amide 
protons was obtained by assuming that 98% of 
the amide protons had exchanged for 2H before 
the first experiment could be measured. The 
intensities of all remaining well-resolved 
signals were fitted to an exponential function  
 
I = I0 exp(kext),     (1) 
 
where I0 is the initial intensity, and kex is the 
exchange rate. All experiments were performed 
on Bruker Avance 600 and 750 MHz 
spectrometers equipped with triple resonance 
probeheads. Under the conditions where our 
experiments were conducted, the so-called EX2 
mechanism of exchange applies (42,43). 
Exchange occurs during breathing motions of 
the protein, which result in the breaking of 
hydrogen bonds, and proton exposure to the 
solvent (the “open state”), enabling pH-
dependent chemical reaction-controlled 
exchange with 2H present in the buffer (44,45). 
The rate of exchange, kex, then is: 
 
kex = kopen/kclose · kintr = Keq · kintr, (2) 
 
where kopen and kclose are the rate of opening and 
closing of the exchanging protein state, kintr is 
the intrinsic rate of exchange for a given amino 
acid type at a given pH (46), and Keq is the 
thermodynamic equilibrium constant for the 
open and closed protein states. Equation 2 thus 
shows that amide proton exchange can report 
on underlying conformational equilibria of the 
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protein. The ratio kintr/kex is commonly referred 
to as the protection factor P, because it 
indicates the degree to which exchange is 
suppressed in the folded protein when 
compared to an unstructured oligopeptide (46). 
The program CARA (www.nmr.ch) was used 
for the analysis of NMR spectra. Fig. 4C was 
prepared using Molmol 2.2 (47).  
 
Mammalian expression constructs and 
plasmid transfection 
For mammalian expression of EB full-length 
FRET constructs the cloning cassettes of the 
bacterial expression vectors (see above) were 
inserted into the backbone of the pEGFP-N1 
mammalian expression vector (Clontech). The 
PCR products of the C-terminally fluorescent 
protein-tagged EB constructs were ligated 
between the HindIII and NotI sites after 
removal of the GFP cassette. Rescue mutations 
were introduced for all EB1 and EB3 full-
length constructs, resulting in five silent 
substitutions in the RNAi target site of EB1 or 
EB3, respectively (9). Plasmids were 
transfected using Fugene 6 (Roche). Plasmids 
expressing fluorescent protein tagged EB 
proteins were co-transfected with a tandem 
pSuper shRNA vector for simultaneous 
depletion of EB1 and EB3 (9). Imaging was 
performed at 2-4 days after transfection. 
 
Live cell imaging and image processing 
For live cell imaging we used a Nikon Eclipse 
Ti-E inverted microscope with perfect focus 
system (PFS) (Nikon), equipped with Nikon 
CFI Apo TIRF 100x 1.49 N.A. oil objective 
(Nikon), QuantEM 512SC EMCCD camera 
(Roper Scientific), and controlled with 
MetaMorph 7.5 software (Molecular Devices). 
For excitation we used a mercury lamp HBO-
100W/2 (Osram) or a 491nm 50mW Calypso 
(Cobolt) or a 561nm 50mW Jive (Cobolt) laser 
(for epi-fluorescence and for TIRF, 
respectively). For simultaneous imaging of 
green and red fluorescent signals we used the 
ET-mCherry/GFP filter set (59022, Chroma) 
together with DualView (DV2, Roper 
Scientific) equipped with a dichroic filter 
565dcxr and a HQ530/30m emission filter 
(Chroma). To keep cells at 37°C we used a 
stage top incubator (model INUG2E-ZILCS, 
Tokai Hit). 16-bit images were projected onto 
the CCD chip at a magnification of 0.065 
μm/pixel with an intermediate magnification of 
2.5X (Nikon C mount adapter 2.5X). Images 
were captured using 500 ms exposures with no 
delay between frames (stream mode). A typical 
image series comprised 100-500 frames, 
measured over a period of 50 s. Images were 
converted to 8 bit format and processed using 
ImageJ with the plug-in "AColor".  
 
RESULTS AND DISCUSSION 
 
Dimerization properties of EBc domains 
Based on native PAGE analysis we previously 
speculated that the mechanism underlying EB 
heterodimer formation involves spontaneous 
exchange of polypeptide chains (9). To further 
investigate this hypothesis we now developed 
an assay based on Förster resonance energy 
transfer (FRET) in a 384-well plate format. 
Cyan and yellow fluorescent proteins (CFP and 
YFP) were fused individually to the N-termini 
of the coiled-coil dimerization domains of the 
three human EBs (Fig. 1A) and milligram 
amounts of the recombinantly expressed fusion 
proteins were purified to homogeneity (referred 
to as CFP-EB1c, YFP-EB1c, CFP-EB2c, YFP-
EB2c, CFP-EB3c, and YFP-EB3c). The 
oligomerization state of the EBc domains in 
solution was assessed by size exclusion 
chromatography (SEC) followed by static light 
scattering (SLS) measurements. The apparent 
molecular masses for the CFP-tagged EB1c, 
EB2c and EB3c domains were 76.9, 79.2 and 
77.8 kDa, respectively, which is consistent with 
the formation of dimers (calculated molecular 
masses for the monomers: CFP-EB1c = 38.4 
kDa, CFP-EB2c = 39.6 kDa, CFP-EB3c = 38.9 
kDa). This data demonstrates that the N-
terminal fluorescent protein tags do not 
interfere with the formation of EBc 
homodimers.  
 Fig. 1B shows the result of a typical 
fluorescence experiment, in which 10 μM CFP-
EB1c was mixed with 10 μM YFP-EB1c and 
incubated for several hours at 37°C 
(throughout, protein concentrations refer to 
monomer equivalents). The excitation 
wavelength was set at 434 nm (CFP maximum) 
and fluorescence spectra were recorded 
between 450 and 650 nm. The fluorescence 
emission spectra displayed a characteristic 
time-dependent transformation which reached 
an apparent equilibrium after about 360 min. 
 7
The reduction of CFP donor emission at 477 
nm with concomitant increase in acceptor YFP 
emission at 527 nm is characteristic of FRET 
for this fluorescence pair (48). Similar spectral 
changes were also observed after mixing 
equimolar amounts of CFP-EB2c and YFP-
EB2c, or CFP-EB3c and YFP-EB3c (not 
shown). In contrast, under the same 
experimental conditions a CFP-tagged 
monomeric mutant of EB1c in which Ile224 
was replaced by alanine (denoted 
EB1c[I224A]; (13)) displayed no significant 
spectral changes after mixing and prolonged 
incubation at 37°C with an equimolar amount 
of YFP-EB1c[I224A] (not shown). The 
monomeric state of EB1c[I224A] was 
confirmed by SEC-SLS experiments, which 
yielded a molecular mass of 38.4 kDa 
(calculated mass for the monomer: 37.3 kDa). 
These results provide a reference, showing that 
the fluorescence assay can be used to monitor 
polypeptide chain exchange of dimeric EBc 
domains in solution, which occured on a time 
scale of minutes to hours under the conditions 
investigated.  
 The increase in fluorescence emission 
at 527 nm was exploited to follow polypeptide 
chain exchange of EBc dimers as a function of 
time. Fig. 1C shows the kinetic profiles 
obtained after mixing equimolar amounts (10 
μM each) of CFP-EB1c and YFP-EB1c, CFP-
EB2c and YFP-EB2c, CFP-EB3c and YFP-
EB3c, or CFP-EB1c[I224A] and YFP-
EB1c[I224A] at 37°C. The traces reveal that 
while both EB1c and EB2c homodimers 
exchange their chains on a similar time scale, 
EB3c homodimers do so much faster. The 
calculated half-time values, t1/2, were 81, 84, 
and 5 minutes for EB1c, EB2c, and EB3c, 
respectively. No significant increase in 
fluorescence emission was detected for the 
monomeric EB1c[I224A] mutant on the time 
scale of the experiment (Fig. 1C).  
 Next we tested the heterodimerization 
properties of the EBc domains. Mixing 
equimolar amounts (10 μM each) of CFP-EB1c 
and YFP-EB3c revealed an increase in 
fluorescence emission with a t1/2 = 84 minutes 
(Fig. 1C). Under the same experimental 
conditions only a small increase in fluorescence 
emission was obtained after mixing equimolar 
amounts of CFP-EB2c and YFP-EB3c, and no 
fluorescence signal was observed after mixing 
CFP-EB1c with YFP-EB2c. These findings 
suggest that significant heterodimerization 
occurs only between EB1c and EB3c chains, 
which is consistent with previous findings 
based on native PAGE analysis (9).  
 The approximately twofold larger 
fluorescence signal increase observed after 
mixing an equimolar amount of YFP-EB3c 
with CFP-EB1c compared to the analogous 
experiments performed with the homodimers 
indicates that a larger fraction of the chains 
form heterodimers than homodimers (Fig. 1C). 
It thus suggests that the EB1c-EB3c 
heterodimer is significantly more stable than 
the homodimers. We estimated the fraction of 
EB1c-EB3c heterodimers formed at various 
molar ratios of the EB1c and EB3c by titrating 
a 10 μM solution of CFP-EB1c with increasing 
amounts of YFP-EB3c and measuring the 
reduction of CFP donor emission at 477 nm 
after incubating for 16 hours at 37 °C. The data 
in Fig. 1D show that at a 1:1 molar ratio about 
80% of the EBc polypeptide chains form EB1c-
EB3c heterodimers. At YFP-EB3c:CFP-EB1c 
molar ratios above 2 nearly all CFP-EB1c 
chains are bound as heterodimers (Fig. 1D). 
 Overall, these experiments demonstrate 
that the C-terminal domains of human EB 
proteins readily exchange their chains in 
solution. They further show that EB1c and 
EB3c preferentially form heterodimers, 
whereas EB2c does not significantly participate 
in heterotypic complexes with its homologues 
under the conditions investigated.  
 
Thermodynamic and kinetic analysis of EBc 
domains 
In view of the pronounced sequence 
identity/similarity of 47/65 %, 60/73 %, and 
50/72 % between human EB1c and EB2c, 
EB1c and EB3c, and EB2c and EB3c, 
respectively, it came as a surprise that human 
EBc domains behave differently with respect to 
their ability to form homo- and heterodimers 
(Fig. 1C). In search of a rationale for these 
differences we determined the thermodynamic 
stabilities, ΔGu, of EB1c, EB2c and EB3c, and 
assessed the rate constants for refolding (kf) 
and unfolding (ku) by stopped-flow 
experiments.  
 For the thermodynamic and kinetic 
experiments the molar per-residue ellipticity 
(MRE) at 222 or 225 nm was used to probe the 
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conformational state of the proteins. Fig. 2A 
shows the results from urea-induced unfolding 
at 25°C with 40 µM protein. For all three 
proteins, the unfolding reaction can be well 
described assuming a two-state equilibrium 
between folded dimer and unfolded monomer 
(36). The transition midpoints, [urea]1/2, differ 
significantly (Suppl Table 1) while the 
steepness of the transitions is comparable, 
indicating differences in stability with similar 
cooperativity. The linear extrapolation method 
adapted to a monomer-dimer equilibrium was 
used to calculate ΔGu and its dependence on the 
denaturant concentration. EB2c (ΔGu = 65 kJ 
mol-1) is slightly more stable than EB1c (ΔGu = 
60 kJ mol-1), whereas EB3c (ΔGu = 49 kJ mol-1) 
is significantly less stable (Suppl Table 1). 
EB1c, EB2c and EB3c also undergo reversible 
thermal unfolding (Fig. 2B). The apparent mid-
points of denaturation, Tm, differ and follow the 
same order as the mid-points of urea 
denaturation: EB2c > EB1c > EB3c (Suppl 
Table 1).  
 The rate of folding (unfolding) of the 
three EBc proteins was studied by following 
the time course of secondary structure 
formation (disruption), after rapid dilution from 
(into) urea at 25 °C. All unfolding traces could 
be fitted as single exponential reactions (not 
shown). The refolding traces were fitted by a 
model assuming bimolecular formation of 
dimers from monomers (not shown). Both the 
refolding and unfolding rate constants 
exponentially depend on the urea concentration 
in the range studied. The Chevron-type plots of 
the data are shown in Fig. 2C and the rate 
constants extrapolated to 0 M Urea are listed in 
Suppl Table 1. The refolding constants 
determined for EB1c (kf = 1.5x105 M-1 s-1) and 
EB3c (kf = 1.3x105 M-1 s-1) are identical within 
the precision of this approach and 7-8 times 
lower than that of EB2c (kf = 9.9x105 M-1 s-1). 
EB2c and EB3c unfold with comparable rates 
(ku = 0.019 and 0.013 s-1, respectively) and are 
30-40 times faster than EB1c (ku = 0.0005 s-1; 
Suppl Table 1). These data reveal that under 
the conditions investigated, EB1c is kinetically 
the most stable protein.  
 The thermodynamic data suggest that 
EB3c is significantly less stable than EB1c and 
EB2c, despite the high sequence similarity of 
the core residues (Fig. 3A). Visual inspection 
of the interactions involved at the protein-
protein interface of an EB3c dimer model (see 
below) did not reveal any peculiarities that 
might explain the decreased stability of EB3c. 
However, it is noteworthy that the two glycine 
residues, 241 and 244 (residue numbering is 
according to the sequence alignment with 
human EB1c throughout), occur in the α2 helix 
of EB3c and are not located at the predicted 
inter-chain interface. Since glycines are well 
known to destabilize α-helices (49), we 
replaced Gly241 and Gly244 in EB3c 
simultaneously by arginine and aspartate, 
which corresponds to the residues in human 
EB1c and EB2c (Fig. 3A; 
EB3c[G241R,G244D]). The shape of the 
thermal unfolding profile as well as the Tm of 
65.1°C obtained for EB3c[G241R,G244D] are 
very similar to that obtained for EB1c (Fig. 
2B). Concomitant with the increase in Tm of 
11.1°C for EB3c[G241R,G244D] when 
compared to EB3c, the t1/2 value of chain 
exchange increased by a factor of 51 to 255 
minutes (not shown). These findings show that 
Gly241 and Gly244 contribute significantly to 
the decreased stability and faster rate of chain 
exchange of EB3c when compared to EB1c and 
EB2c.  
 
Model building 
In order to extend our thermodynamic and 
kinetic studies we generated molecular models 
for the presently studied dimers based on the 
crystal structure of the human EB1c 
homodimer (see Experimental Procedure). 
Analysis of a sequence alignment of 
mammalian EB1c, EB2c and EB3c domains 
(Fig. 3A) coupled with visual inspection and 
stereochemical analysis of the interchain 
interfaces of the models did not provide clues 
to rationalize why EB1c preferentially forms 
heterodimers with EB3c. However, in the case 
of EB2c, which does not significantly form 
heterodimers with EB1c and EB3c, the models 
allowed us to identify two non-conserved 
dipeptide segments of interest, i.e., Thr206-
Val207 and Val238-Leu239 (Fig. 3A). These 
two dipeptide segments display favorable 
interchain interactions in the X-ray structure of 
the EB1c homodimer and in the modeled 
EB1c-EB3c heterodimer (Fig. 3, B and C), but 
they exhibit unfavorable packing in the EB2c-
EB1c/EB2c-EB3c heterodimers (Fig. 3, D and 
E). Fig. 3D shows that in the EB2c-
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EB1c/EB2c-EB3c interfaces, Ala206 of EB2c 
is too short for an optimal van der Waals 
contact with Val207 of EB1c/EB3c, while 
Leu207 of EB2c is too bulky and sterically 
clashes with Thr206 of EB1c/EB3c. In Fig. 3E, 
Leu238 of EB2c forces Leu/Ile239 of 
EB1c/EB3c to adopt unusual rotamer states, 
while Val239 of EB2c is too short for an 
optimal interaction with Val238 of EB1c/EB3c. 
By comparison, optimal packing is represented 
in Fig. 3E by the similarly positioned Val238 
and Leu239 residues in the EB1c homodimer.  
 To test whether the two non-conserved 
dipeptide segments in the EBc domains are 
responsible for preventing heterodimer 
formation by EB2c, we generated a set of EB2c 
mutants and tested their ability to form 
heterodimers with EB3c using our fluorescence 
assay. In the first mutant we replaced Leu238 
and Val239 of EB2c by the corresponding 
EB1c residues valine and leucine, respectively 
(YFP-EB2c[L238V,V239L]). As shown in Fig. 
3F, at equilibrium, an equimolar mixture (10 
μM each) of CFP-EB3c with YFP-
EB2c[L238V,V239L] displayed a stronger 
fluorescence emission at 527 nm when 
compared to an equimolar mixture of CFP-
EB3c with YFP-EB2c, which is indicative of 
heterodimer formation. The fluorescence 
intensity was in between the signals obtained 
for a sample containing 10 μM each of CFP-
EB3c and YFP-EB2c (no chain exchange), and 
a sample containing 10 μM each of CFP-EB3c 
and YFP-EB3c (Fig. 3F) suggesting that the 
homodimers are favored over the heterodimer. 
In a second mutant, Ala206 and Leu207 of 
YFP-EB2c[L238V,V239L] were substituted 
with the corresponding EB1c residues 
threonine and valine, respectively (YFP-
EB2c[A206T,L207V,L238V,V239L]). When 
10 μM of this mutant was incubated with 10 
μM of CFP-EB3c it displayed a fluorescence 
emission comparable to the one obtained for 10 
μM each of CFP-EB3c and YFP-EB3c 
suggesting that the homo- and heterodimers are 
equally stable (Fig. 3F). The data of the two 
mutants of EB3c indicate that multiple 
elements dispersed along the coiled coil and 
four-helix bundle contribute to homo- versus 
heterotypic chain selection.  
 In combination with the 
thermodynamic and kinetic data (see above), 
these findings show that in spite of their high 
sequence similarities, mammalian EBc 
domains exhibit different biophysical 
properties, and suggest that substitutions within 
the EBH domain contribute to the differential 
stabilities and rate of chain exchange of the 
EBc variants. They further show that variable 
packing interactions at the dimer interface 
determine whether EBc domains preferentially 
form homo- or heterodimers.  
 
Effects of EB1c-binding partners on chain 
exchange 
To investigate possible impact of binding 
partners on chain exchange of EBc domains we 
executed our fluorescence assay in the presence 
of several different +TIP domains. The first set 
of experiments was performed with CAP-Gly 
domains, which target the C-terminus of EB 
proteins. Prominent members of CAP-Gly 
+TIPs are CLIP-170 and p150glued. We 
recombinantly expressed and purified the 
second CAP-Gly domain of CLIP-170 
(ClipCG2), the CAP-Gly domain of p150glued 
(p150CG) and a mutant of p150CG in which 
Ala49 was mutated to methionine 
(p150CG[A49M]). The affinities of the three 
CAP-Gly domains for EB1c have been 
determined previously by isothermal titration 
calorimetry (15,33). The dissociation constants, 
Kd, were 29.7 μM for ClipCG2, 2.7 μM for 
p150CG and 0.17 μM for p150CG[A49M], 
with the stoichiometries for all complexes 
corresponding to 2 mol CAP-Gly domain per 1 
mol of EB1c dimer. CFP-EB1c and YFP-EB1c 
(10 μM each) were mixed separately with 
different CAP-Gly domains and the increase in 
fluorescence emission at 527 nm (excitation at 
434 nm) was monitored at 37°C during an 
incubation time of 600 minutes. The amount of 
CAP-Gly domain added was adjusted such that 
95% of the EB1c molecules are complexed.  
 Fig. 4A documents that ClipCG2 
increased the t1/2 of chain exchange of EB1c 
about two-fold. In contrast, p150CG caused a 
10- to 20-fold increase in t1/2 of chain exchange, 
and for the duration of the experiment of 600 
minutes; p150CG[A49M] suppressed chain 
exchange completely. The differences in 
potency of the various CAP-Gly domains can 
be explained based on their binding 
mechanisms. ClipCG2 primarily targets the C-
terminal EEY tripeptide of EB1c (Fig. 1A) 
using its highly conserved GKNDG motif (33). 
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Binding to the two C-terminal tail regions of 
EB1c, which are flexibly disordered in solution 
(14), is not expected to interfere significantly 
with EB1c chain exchange, consistent with the 
experiment (Fig. 4A). In contrast, each 
p150CG molecule uses its GKNDG motif to 
bind the C-terminal EEY tripeptide of one 
EB1c dimer and its β2-β3 loop to interact with 
the hydrophobic cavity and the polar rim of the 
EBH domain formed by highly conserved 
residues stemming from both monomers of the 
dimer (Fig. 1A) (33). The simultaneous binding 
of p150CG to both chains of EB1c explains the 
inhibition of chain exchange. This effect is 
enhanced for p150CG[A49M], which displays 
a 15-fold higher affinity for EB1c when 
compared to the wild-type domain. The 
increased affinity can be rationalized by the 
improved packing of the methionine side chain 
against the hydrophobic cavity of the EBH 
domain when compared to the alanine present 
in the wild type CAP-Gly domain (33).  
 Another prominent +TIP member that 
binds to the C-terminus of EB1 is APC. A 
fragmentation study revealed that a 39-residue 
polypeptide segment derived from the C-
terminus of APC is sufficient for binding to 
EB1c with a Kd of 5.1 μM (12,14,18). A 
peptide encompassing the EB1-binding site of 
APC (denoted APCp1) completely inhibited 
EB1c chain exchange on the time scale of the 
experiment (Fig. 4A). Structural analysis of the 
EB1c-APCp1 complex revealed that APCp1 
tightly binds with its SxIP motif to the interface 
formed between the two EB1c monomers (14), 
which is consistent with its strong inhibitory 
effect on chain exchange. Compared to 
p150CG, which displays a comparable affinity 
for EB1c as APCp1, the binding mechanism 
used by APCp1 appears more efficient in 
suppressing chain exchange (Fig. 4A). This 
difference may be explained by the observation 
that APCp1 interacts more extensively with the 
EBH domain than p150CG and possibly also 
because the binding of APCp1 induces 
structure in the C-terminal  segment of EB1c 
(14,33).  
 Overall, these experiments show that 
chain exchange of mammalian EBc domains 
can be differentially controlled by binding 
partners.  
 
 
NMR analysis of the EB1c-APCp1 complex 
We characterized the influence of APCp1 on 
the stability of the EB1c homodimer in more 
detail using amide hydrogen exchange 
monitored by NMR. In this method, the 
uniformly 15N-labeled protein is lyophilized 
from an 1H2O buffer, and then redissolved in 
2H2O. Two-dimensional [15N,1H]-correlation 
NMR experiments recorded with 1H2O and 
2H2O solutions of the protein then reveal the 
extent of 1HN → 2HN exchange, since 2HN 
signals do not contribute to the signal 
intensities. Within the dead time of about 10 
minutes for the presently used 37°C exchange 
experiment, a large number of amide protons of 
EB1c have exchanged completely and are no 
longer detected in the first spectrum of the 
exchange series (compare Suppl Fig. 1, A and 
C), so that we can only estimate an upper 
bound on the protection factors (see 
Experimental Procedure). These rapidly 
exchanging residues are in positions 191–208 
of the N-terminal part of the coiled coil, 231–
241 of the loop connecting the helices α1 and 
α2, and 247–268 of the flexible C-terminal tail 
of EB1c (Fig. 4B). A second set of amide 
group signals were visible in the first exchange 
spectrum (Suppl Fig. 1C), and fits to 
exponential decays yielded exchange rates of 
0.05 to 0.14 min-1, with corresponding 
protection factors of 1600–57000 (log P = 3.2–
4.7); these signals are assigned to residues 209–
230 and 242–246, which form the core of the 
highly conserved EBH domain. These data 
indicate that the EBH domain is the most stable 
part of EBc, explaining why even conservative 
substitutions in this part of the protein can have 
a strong impact on stability, as seen, for 
example, for the monomeric single-site mutant 
EB1c[I224A] (see above).  
 When the amide proton exchange 
experiment was performed in the presence of 
an equimolar amount of APCp1 and otherwise 
identical experimental conditions, the residues 
191–202, 231–241, and 249–268 were again 
completely exchanged within 10 minutes 
(Suppl Fig. 1, B and D), whereas the residues 
203–230 and 242–248 showed a large 
reduction of the exchange rates to 0.00015–
0.049 min-1, with corresponding protection 
factors of 2700–3.2·106 (log P = 3.4–6.5). Two 
regions show a plateau with high protection 
factors, i.e., residues 212–228 of the helix α1 
 11
and residues 242–246 of the helix α2 (Fig. 4B). 
These helical segments form the core of the 
EBH domain structure (Fig. 4C). Both of these 
regions show a significant increase in 
protection of 1.5 to 2 orders of magnitude in 
the presence of APCp1 (Fig. 4, B and C). 
Although both helices show a large increase in 
protection, helix α2 stands out because its 
residues show a uniform set of protection 
factors in the complex, suggesting that the 
exchange of all these amide protons is 
governed by the same molecular process. 
Possibly this feature in the exchange profile 
reflects a separation of helix α2 from the pair 
of α1 helices, which could represent a first step 
in the release of APCp1 that would precede 
monomer exchange. We found that the glycine 
residues at positions 241 and 244 in EB3c 
account for most of the difference in stability 
and rate of chain exchange between EB1c and 
EB3c (see above). Both of these substitutions 
introduce a residue that is unfavorable for the 
formation of the helix α2, suggesting that chain 
exchange of EB3c may be facilitated by a 
destabilizing effect of these substitutions in 
helix α2. This would also be consistent with a 
mechanism for chain exchange involving the 
release of helix α2 from the EBH domain (see 
above).  
 The amide proton exchange data of 
EB1c obtained in the presence and absence of 
APCp1 show that the intramolecular hydrogen 
bond network is stabilized by the bound 
peptide. Because this network includes residues 
from the entire EBH domain (Fig. 4C) it 
appears likely that the increase of protection 
indicates enhanced stability of the dimer, so 
that a smaller fraction of monomer would be 
available for chain exchange when APCp1 is 
bound. The largest increase in protection 
factors upon binding APCp1 is at the central 
interface between the two monomers formed by 
the helices α1 and α2. The implicated 
stabilization of this interface region in the 
EB1c-APCp1 complex is consistent with the 
greatly reduced extent of chain exchange 
observed in the fluorescence assay (Fig. 4A) 
and may explain how APCp1 achieves efficient 
suppression of chain exchange despite its 
comparably modest affinity for EB1c.  
 Overall, these findings indicate that 
suppression of chain exchange of EB1c by 
APCp1 is accomplished primarily by 
preventing the release of helix α2 from the 
EBH domain.  
 
Dimerization properties of full-length EB1 
and EB3 in vitro 
In order to extend the studies of chain exchange 
on the C-terminal domains of EB1 and EB3 
(Fig. 1C) to the full-length proteins we 
individually fused CFP and YFP to the C-
termini of EB1 and EB3 (referred to as EB1-
CFP, EB1-YFP, EB3-CFP and EB3-YFP) and 
assessed chain exchange with the same 
fluorescence assay as for the EBc domains. The 
oligomerization state of EB1-CFP in solution 
was found to be dimeric by SEC-SLS 
measurements, which yielded a molecular mass 
of 118.2 kDa (calculated molecular mass for 
the monomer: 58.3 kDa), demonstrating that C-
terminal tagging of full-length EBs with a 
fluorescent protein does not interfere with 
formation of the native dimeric structure.  
 Upon mixing equimolar amounts (10 
μM each) of EB1-CFP with EB1-YFP or EB3-
CFP with EB3-YFP at 37°C we observed 
spontaneous chain exchange of both 
homodimers, as evidenced by a time-dependent 
increase of fluorescence emission at 527 nm 
(excitation at 434 nm) (Fig. 5A). The 
significantly stronger signal obtained at 
equilibrium for EB1 when compared to EB3 
could be due to the four residue shorter C-
terminal tails of the EB1 dimer, which reduces 
the average distance between the two 
fluorescent protein pairs. Evaluation of the 
kinetic profiles yielded t1/2 values of 63 and 38 
minutes for EB1 and EB3, respectively. In 
contrast, no significant increase in fluorescence 
was detected for the monomeric fluorescent-
protein tagged EB1 mutant where Ile224 was 
replaced by alanine (denoted EB1[I224A]-CFP 
and EB1[I224A]-YFP). The monomeric state 
of EB1[I224A]-CFP was confirmed by SEC-
SLS experiments, which yielded a molecular 
mass of 60.0 kDa (calculated molecular mass 
for the monomer: 58.3 kDa). The t1/2 value for 
chain exchange of EB1 (63 minutes) is 
comparable to the one obtained for EB1c (81 
minutes); the significant increase of the t1/2 
value for EB3 (38 minutes) compared to EB3c 
(5 minutes) indicates that the EB3 dimer is 
stabilized in the full-length protein relative to 
the dimeric EB3c fragment.  
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 Mixing equimolar amounts (10 μM 
each) of EB1-CFP and EB3-YFP also revealed 
a time-dependent increase in fluorescence 
emission which is indicative of heterodimer 
formation with t1/2 = 83 minutes (Fig. 5A). The 
ability of full-length EB1 and EB3 to form 
heterotypic complexes is consistent with 
previous findings based on 
immunoprecipitation experiments (9). A 
stronger fluorescence signal at steady state was 
observed after mixing EB1-CFP with EB3-YFP 
than in the solutions of the homodimers, 
indicating that similar to the EBc domains, the 
heterodimer of the full-length proteins is more 
stable than the homodimers.  
 As mentioned in the introduction, C-
terminal domains of EBs are frequently used in 
cellular studies as dominant negative mutants 
that interfere with the activity of endogenous 
EB proteins. To probe the ability of EB3c to 
form heterodimers with full-length EB1 we 
performed SEC-SLS experiments. As shown in 
Fig. 5B, EB1-CFP and EB3c applied separately 
onto a SEC column eluted as single peaks at 
12.8 and 14.9 ml, respectively, and the 
molecular masses determined for both proteins 
were consistent with the formation of dimers 
(Fig. 5B). Injection of an equimolar mixture of 
EB1-CFP and EB3c (10 μM each) which had 
been pre-incubated for 16 hours at 37 °C, 
revealed a single peak that displayed an 
increase in elution volume of 0.8 ml with 
respect to EB1-CFP (Fig. 5B). Molecular mass 
determination by SEC-SLS yielded a value of 
68.0 kDa, which corresponds to an EB1-
CFP/EB3c heterodimer (calculated molecular 
mass is 58.3 (EB1-CFP monomer) + 9.7 (EB3c 
monomer) = 68.0 kDa).  
 Collectively, these data show that just 
as for the C-terminal domains of EB1 and EB3 
the full-length proteins also readily exchange 
their chains in solution. They further reveal that 
EB1 forms heterodimers with EB3, and that the 
C-terminal domain of EB3 can displace an EB1 
monomer in the full-length EB1 dimer.  
 
Dimerization properties of full-length EBs in 
cells 
Here we extend the in vitro studies by 
investigations of the ability of full-length EBs 
to heterodimerize in cells. We have previously 
shown that in an EB1/EB3 knockdown 
background a monomeric CH domain construct 
of EB3 can, although weakly, autonomously 
track growing microtubule ends in cells (9). 
Therefore, if EB1 and EB3 do efficiently 
heterodimerize in cells, then EB3 should be 
able to target an EB1 version with a mutated 
CH domain, which is incapable of plus-end 
tracking on its own, to growing microtubule 
ends. Lys59 and Lys60 of EB1 were shown to 
be essential for microtubule binding (50), and 
mutation of these two residues to glutamic 
acids completely abolished plus-end tracking of 
EB1 C-terminally tagged with the red 
fluorescent protein mCherry 
(EB1[K59E,K60E]-mCherry) in an EB1/EB3 
knockdown background (Suppl Fig. 2). 
However, EB1[K59E,K60E]-mCherry was 
recruited to the growing microtubule plus ends 
when co-expressed together with EB3-GFP in 
cells depleted in EB1 and EB3 (Fig. 5C; Suppl 
Movie 1). As a control, we used the monomeric 
version of EB1[K59E,K60E]-mCherry 
containing the I224A mutation 
(EB1[K59E,K60E,I224A]-mCherry), and as 
expected this protein was not recruited to the 
growing microtubule ends upon coexpression 
with EB3-GFP (Fig. 5D; Suppl Movie 2). 
Similarly, EB2[K59E,K60E]-mCherry and 
EB1[K59E,K60E]-mCherry were not 
relocalized to growing microtubule ends by 
EB3-GFP (Fig. 5E; Suppl Movie 3) and EB2-
GFP (Fig. 5F; Suppl Movie 4), respectively, 
which is in agreement with lack of significant 
heterodimerization between EB2c and the other 
two EBc domains in vitro (Fig. 1C).  
 The combined results of the above 
experiments support the view that in cells, full-
length EB1 heterodimerizes with EB3 but not 
with EB2. It should be noted, however, that we 
previously observed a dominant negative effect 
on the endogenous EB2 pool when the EB1c 
domain was overexpressed in cells (9). A 
possible explanation of this observation could 
be that under overexpression conditions, EB1c 
sequesters the much lower cellular levels of 
EB2.  
 
Conclusions 
This study provides a detailed description of 
the dimerization properties of the three human 
EB proteins, which is controlled by their C-
terminal dimerization domains. EB dimers 
were found to readily exchange their chains on 
a time scale of minutes to hours. The data 
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reveal that EB1 preferentially heterodimerizes 
with EB3, while EB2 does not significantly 
form heterotypic complexes. They further 
suggest that chain exchange of EBs can be 
differentially suppressed by +TIP binding 
partners.  
 Our findings have important functional 
implications. Based on the present data we 
anticipate that in cells expressing lower levels 
of EB3 than of EB1, a large fraction of the EB3 
pool will be tied up into EB1-EB3 
heterodimers. Heterotypic complex formation 
between EB1 and EB3 thus generates an 
additional EB variant, which is expected to 
display yet a different functional profile when 
compared to its homotypic counterparts. Our 
findings also suggest that in cells EBs are not 
present in separate pools, but rather form a 
common pool undergoing continuous exchange 
within the cytoplasm. A consequence of this 
consideration is that in cells that co-express 
different EB species, their functions cannot be 
contemplated and analyzed separately from 
each other. Our observation that +TIP binding 
partners suppress chain exchange further 
indicates that this stabilization mechanism 
could have regulatory consequences for EBs in 
cells, for example, in the spatial and temporal 
degradation of EBs (21). The dimerization of 
EBs is necessary to preserve their function of 
promoting persistent microtubule growth by 
suppressing catastrophes (9). Modulation of 
dimerization of EBs is thus an additional route 
to regulation of microtubule dynamics and 
function, an aspect that adds exciting prospects 
for future studies addressing the molecular 
mechanisms of EBs.  
 An important finding of our study is 
that the C-terminal domain of EB3 can interact 
with full-length EB1, resulting in a truncated 
heterodimer with only one CH domain. 
Transient overexpression of EB1 or EB3 C-
terminal domains has been used as a tool in 
many studies with the intent to interfere with 
the binding of +TIPs with endogenous full-
length EBs in different cell types (9,20,25-32). 
We recently showed that a very similar 
dominant negative effect is also obtained with 
an EB1 C-terminal domain lacking the tail 
region, which is essential for partner binding 
(9), indicating that sequestration of +TIP 
binding partners is not the prevailing mode of 
interference. The analysis presented here 
strongly suggests that the primary mechanism 
of the dominant negative effect of coexpressed 
C-terminal EB domains is to knockdown all EB 
species by heterodimerization with the 
endogenous full-length proteins, which results 
in a strong reduction in their localization at 
microtubule plus ends due to the presence of 
only one functional CH domain in EBc-EB 
heterodimers.  
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FIGURE LEGENDS 
 
Fig. 1. Heterodimerization of EBc domains. A, Schematic diagram showing FRET of dimeric EBc 
domains that are N-terminally tagged with fluorescence proteins. CFP absorbs light at 434 nm and 
emits light at 477 nm. YFP absorbs light at 514 nm and emits light at 527 nm. When brought in 
close proximity, for example, through the coiled-coil domains of EBc dimers, energy absorbed by 
CFP is transferred to YFP through nonradiative FRET and emitted by YFP. B, Fluorescence 
emission spectra obtained by mixing equimolar amounts of CFP-EB1c and YFP-EB1c (10 μM 
each) at 37°C and recorded at 60 minute time intervals with excitation at 434 nm. Red and green: 
spectra obtained after 0 and 600 minutes incubation time, respectively. Note that the fluorescence 
emission signal at 527 nm observed at time 0 is due to background FRET in the sample (Suppl Fig. 
3). C, Time-dependent increase of fluorescence signal at 527 nm (excitation at 434 m) after mixing 
equimolar amounts (10 μM each) of CFP-EB1c and YFP-EB1c (1c), CFP-EB2c and YFP-EB2c 
(2c), CFP-EB3c and YFP-EB3c (3c), CFP-EB1c and YFP-EB2c (1c/2c), CFP-EB1c and YFP-EB3c 
(1c/3c), CFP-EB2c and YFP-EB3c (2c/3c), and CFP-EB1c[I224A] and YFP-EB1c[I224A] 
(1c[I224A]) at 37 °C. D, Titration of 10 μM CFP-EB1c with increasing amounts of YFP-EB3c. The 
data show the loss of intensity of the fluorescence signal at 477 nm due to the dequenching of CFP-
EB1c homodimers because of EB1c-EB3c heterodimer formation. Samples were incubated at 37°C 
for 16 hours prior to each measurement.  
 
Fig. 2. Thermodynamic and kinetic properties of EBc domains. A, Isothermal urea-induced 
unfolding at 25°C with 40 µM protein. Experimental data are represented by filled circles. 
Continuous lines show the best fits obtained assuming a monomer-dimer equilibrium model. B, 
Thermal unfolding with 50 µM protein. Same presentation as in (A). C, Urea dependence of the rate 
constants for refolding (solid symbols) and unfolding (open symbols) at 25°C measured by stopped-
flow experiments. The rate constants under native conditions are calculated by extrapolation of the 
linear regression lines to 0 M urea. In all panels the data are color-coded: green, EB1c (1c); blue, 
EB2c (2c); red, EB3c (3c); brown, EB3c[G241R,G244D] (3c[G241R,G244D]). The data shown 
correspond to the mean residue ellipticities at 222 nm (A and B) or at 225 nm (C).  
 
Fig. 3. Structural analysis of EBc domains. A, Multiple sequence alignment of human (h), murine 
(m) and rat (r) EB1c, EB2c and EB3c. Residues of EB1c involved in interchain interactions (based 
on PDB entry 1WU9) are highlighted in green and their size conservation among similar residue 
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types is indicated in bold. The locations of the helices α1 and α2 in the structure of the EB1c 
homodimer and the residue numbering of EB1c are indicated above the alignment. The sites 
investigated in the mutational study (see text and panel F) are shaded in gray; Gly241, Gly244 in 
EB3h and Ile224 in EB1h are underlined. All residue positions are given according to the alignment 
with the EB1 sequence. B and C, Close-up views of the model of the human EB1c-EB3c 
heterodimer (EB1c and EB3c chains are depicted in light green and red, respectively) superimposed 
onto the crystal structure of the human EB1c homodimer (depicted in dark green). The main chains 
are shown as ribbons, and the interacting side chains in stick representation. The labels are in the 
color of the corresponding chains, or in black when the same residue occurs in both superimposed 
chains. Panel B shows the dipeptide segment 1 and panel C the dipeptide segment 2 (see text). D 
and E, Close-up view of the model of the human EB2c-EB3c heterodimer (EB2c and EB3c chains 
depicted in blue and red, respectively) superimposed onto the crystal structure of the human EB1c 
homodimer (depicted in dark green). Panel D shows the dipeptide segment 1, panel E the dipeptide 
segment 2. The residue numbering is according to the EB1 sequence (see panel A). Oxygen atoms 
of side chains in the panels B to E are indicated in yellow. F, Effect of mutations in EB2c on chain 
exchange with EB3c. Fluorescence emission spectra (excitation at 434 nm) recorded from 
equimolar mixtures (10 μM each) of CFP-EB3c with YFP-EB1c (3c/1c, magenta), YFP-EB2c 
(3c/2c, cyan), YFP-EB3c (3c, red), YFP-EB2c[L238V,V239L] (3c/2c[L238V,V239L], grey) and 
YFP-EB2c[A206T,L207V,L238V,V239L] (3c/2c[A206T,L207V,L238V,V239L], dark grey). 
Samples were incubated at 37°C for 16 hours prior to data acquisition.  
 
Fig. 4. Effect of binding partners on EB1c chain exchange. A, Time-dependent increase of the 
fluorescence signal at 527 nm (excitation at 434 m) after mixing equimolar amounts (10 μM each) 
of CFP-EB1c and YFP-EB1c at 37°C in the absence of a binding partner and in the presence of 
either 591 μM ClipCG2, 65 μM p150CG, 23 μM p150CG[A49M], or 116 μM APCp1. The 
concentrations of the EB1c-binding partners have been adjusted so that 95 % of the EB1c is present 
in complexed form when taking the Kd values of the individual binding partners into account 
(15,33). B, Amide 1H exchange protection factors of EB1c in the absence (blue) and presence (red) 
of an equimolar amount of APCp1. No data are shown for residues 207, 211 and 215 in the complex 
because of resonance overlap, and for the residues 237, 256 and 261 in both data sets because these 
residues are prolines. Residues 191–208 and 231–241 from the free EB1c and residues 191–202, 
231–241, and 249–268 from EB1c in complex with APCp1 are not shown because their amide 
protons have completely exchanged before the first experiment could be started (about 10 min), 
corresponding to log P values ≤ 3. The locations of the helices α1 and α2 in the structure of the 
EB1c homodimer (PDB entry 1WU9) are indicated above the horizontal scale. C, Location of 
slowly exchanging amide hydrogens in the structure of the free EB1c dimer (left) and the EB1c 
dimer in complex with MACFp1 (right), which was shown to form a closely similar complex to the 
one with APCp1 (14). The backbone is shown in grey and selected residue positions are indicated. 
The exchange data are represented by color-coded spheres at the position of the backbone N atoms: 
light blue, fast exchanging 1H, not observed in the first exchange spectrum; yellow, log P < 4; 
orange, log P = 4.0-5.0; red, log P > 5. The locations of the bound peptides are indicated by a green 
tube representing a spline function through the Cα atom coordinates.  
 
Fig. 5. Heterodimerization of full-length EB1 and EB3. A, Time-dependent increase of the 
fluorescence signal at 527 nm (excitation at 434 m) after mixing equimolar amounts (10 μM each) 
of EB1-CFP and EB1-YFP (1), EB3-CFP and EB3-YFP (3), EB1-CFP and EB3-YFP (1/3) and 
EB1[I224A]-CFP and EB1[I224A]-YFP (1[I224A]) incubated at 37°C. B, SLS-SEC experiments of 
EB1-CFP (1), EB3c (3c) and a mixture of EB1-CFP and EB3c (1/3c) that has been incubated for 16 
hours at 37°C. Molecular mass determination (colored horizontal lines located below the maximum 
of each peak) yielded values of 118.2 kDa for EB1-CFP, 18.2 kDa for EB3c, and 68.0 kDa for 
EB1-CFP/EB3c. C to F, Heterodimerization of full-length EB proteins in cells. CHO cells were co-
transfected with shRNA plasmids to deplete endogenous EB1 and EB3 and co-transfected with the 
indicated combination of fluorescent protein tagged EBs. GFP and mCherry fluorescence were 
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imaged simultaneously using TIRF microscopy. Images were obtained at 0.5 sec intervals and 5 
consecutive frames were averaged. Each panel shows a maximum intensity projection of 20 
averaged frames, where each odd frame is shown in green and each even frame in red. Growing 
microtubule ends appear in this representation as rows of alternating green and red dashes. Note that 
EB3-GFP and EB2-GFP display robust plus-end tracking. EB1[K59E,K60E]-mCherry is recruited 
to plus ends by EB3-GFP (C). The I224A mutation which interferes with dimerization of 
EB1[K59E,K60E,I224A]-mCherry abrogates recruitment by EB3-GFP (D). EB3-GFP does not 
recruit EB2[K59E,K60E]-mCherry (E). In contrast to EB3-GFP, EB2-GFP fails to recruit 
EB1[K59E,K60E]-mCherry to growing microtubule ends (F).  
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